Genome Biologics

Genome Biologics develops RNAi therapies for cardiovascular and cardiometabolic disease, targeting specific tissue.

General Information
Company Name
Genome Biologics
Founded Year
2017
Location (Offices)
Founders / Decision Makers
Number of Employees
-
Industries
-
Funding Stage
-
Social Media

Genome Biologics - Company Profile

Genome Biologics is a biotech startup founded in 2017 with a mission to develop innovative RNA interference (RNAi) therapies for cardiovascular and cardiometabolic diseases. They have pioneered cutting-edge RNAi interventions tailored for specific tissues to target the transcriptome of these diseases, addressing a vital need in the medical field. Their state-of-the-art technology platforms allow for the expedited creation of RNAi therapies, offering promising solutions where current treatments are ineffective or absent. Genome Biologics presents an exciting opportunity for venture capitalists seeking to invest in the forefront of biotechnology and medical innovation.

Taxonomy: RNAi therapies, Cardiovascular disease, Cardiometabolic disease, Transcriptome targeting, Tissue-specific treatments, RNA interference, Therapeutic innovation

Funding Rounds & Investors of Genome Biologics (0)

View All

There is no investment information

Latest News of Genome Biologics

View All

No recent news or press coverage available for Genome Biologics.

Similar Companies to Genome Biologics

View All
TAmiRNA GmbH - Similar company to Genome Biologics
TAmiRNA GmbH stability for life
Phio Pharmaceuticals Corp. - Similar company to Genome Biologics
Phio Pharmaceuticals Corp. Phio’s proprietary RNA interference (RNAi) technology makes immune cells more effective in killing tumor cells.
Sanegene Bio - Similar company to Genome Biologics
Sanegene Bio Dedicated to developing novel life-changing RNAi therapeutics
OliX Pharmaceuticals, Inc. - Similar company to Genome Biologics
OliX Pharmaceuticals, Inc. Contributing to the Health and Happiness of Mankind with RNAi Technology